Literature DB >> 17688835

Inflammatory muscle disease: clinical presentation and assessment of patients.

Helene Alexanderson1, Ingrid E Lundberg.   

Abstract

Muscle weakness and muscle fatigue are the most common manifestations in patients with idiopathic inflammatory myopathies (ie, myositis), but other organs are frequently involved such as skin, lungs, joints, and the heart. These could occur before, simultaneously with, or after the onset of muscle symptoms. One tool to structure outcome measure is the International Classification of Functioning, Disability, and Health. Measures of "disability" can be divided into impairment and activity limitation/participation restriction. Most of the available outcome measures for myositis could be classified as measures of impairment, such as muscle strength, serum levels of muscle enzymes, and pulmonary function tests. Measures of activity limitation/participation restriction are also important, such as the myositis activities profile, the visual analog scale to assess impact on general well-being, and the generic short form-36 to capture impact on health-related quality of life.

Entities:  

Mesh:

Year:  2007        PMID: 17688835     DOI: 10.1007/s11926-007-0044-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

1.  Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen.

Authors:  G J D Hengstman; W T M Vree Egberts; H P Seelig; I E Lundberg; H M Moutsopoulos; A Doria; M Mosca; J Vencovsky; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

2.  Pathologic skeletal muscle perfusion in patients with myositis: detection with quantitative contrast-enhanced US--initial results.

Authors:  Marc-André Weber; Martin Krix; Uta Jappe; Hagen B Huttner; Marius Hartmann; Uta Meyding-Lamadé; Marco Essig; Christoph Fiehn; Hans-Ulrich Kauczor; Stefan Delorme
Journal:  Radiology       Date:  2005-12-21       Impact factor: 11.105

Review 3.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

4.  A functional index in myositis.

Authors:  A Josefson; E Romanus; J Carlsson
Journal:  J Rheumatol       Date:  1996-08       Impact factor: 4.666

5.  Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.

Authors:  Patrick Cherin; S Pelletier; A Teixeira; P Laforet; T Genereau; A Simon; T Maisonobe; B Eymard; S Herson
Journal:  Arthritis Rheum       Date:  2002-02

6.  Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.

Authors:  M G Danieli; G Malcangi; C Palmieri; F Logullo; A Salvi; M Piani; G Danieli
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

Review 7.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

8.  Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis.

Authors:  J H Park; T L Vital; N M Ryder; M Hernanz-Schulman; C L Partain; R R Price; N J Olsen
Journal:  Arthritis Rheum       Date:  1994-05

Review 9.  NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy.

Authors:  P H Plotz; L G Rider; I N Targoff; N Raben; T P O'Hanlon; F W Miller
Journal:  Ann Intern Med       Date:  1995-05-01       Impact factor: 25.391

Review 10.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.

Authors:  Pedram Gerami; Jennifer M Schope; Lauren McDonald; Hobart W Walling; Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2006-01-23       Impact factor: 11.527

View more
  3 in total

1.  Quality of life correlates with muscle strength in patients with dermato- or polymyositis.

Authors:  Karina B Poulsen; Helene Alexanderson; Christine Dalgård; Søren Jacobsen; Louise Weile; Louise P Diederichsen
Journal:  Clin Rheumatol       Date:  2017-06-06       Impact factor: 2.980

Review 2.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

3.  Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis.

Authors:  Melina Andrade Mattar; Bruno Gualano; Luiz Augusto Perandini; Samuel Katsuyuki Shinjo; Fernanda Rodrigues Lima; Ana Lúcia Sá-Pinto; Hamilton Roschel
Journal:  Arthritis Res Ther       Date:  2014-10-25       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.